Universe Pharmaceuticals INC UPC
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-8.06
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.86B | $23.02B | $32.31B | $40.1M | $48.0M | $30.7M | $33.2M | — |
| Cost of revenue | $11.56B | $16.95B | $21.99B | $18.3M | $22.7M | $16.6M | $19.8M | — |
| Gross profit | $6.30B | $6.07B | $10.32B | $21.9M | $25.3M | $14.1M | $13.4M | — |
| R&D | $671.8M | $3.03B | $4.86B | $7.6M | $5.5M | $583.1K | $618.4K | — |
| SG&A | $3.75B | $2.89B | $2.64B | $2.2M | $3.3M | $1.7M | $1.5M | — |
| Total operating expenses | $9.22B | $14.09B | $14.28B | $28.9M | $11.7M | $3.8M | $3.7M | — |
| Operating income | -$2.92B | -$8.02B | -$3.97B | -$7.0M | $13.6M | $10.3M | $9.8M | — |
| Interest expense | $289.4M | $304.5M | $190.2M | $162.4K | $101.6K | $123.8K | $129.3K | — |
| Pre-tax income | -$3.67B | -$8.12B | -$4.33B | -$7.1M | $13.7M | $10.1M | $9.7M | — |
| Income tax | — | $606.7M | $2.25B | $815.3K | $2.4M | $2.5M | $2.1M | — |
| Net income | -$3.67B | -$8.73B | -$6.58B | -$7.9M | $11.3M | $7.6M | $7.6M | — |
| EPS, basic | -8.06 | -626.96 | -1,089.21 | -1,309.11 | 3.58 | 0.47 | — | — |
| EPS, diluted | -8.06 | -626.96 | -1,089.21 | -1,309.11 | 3.58 | 0.47 | 0.47 | — |
| Shares, diluted (wtd. avg.) | 455,871 | 13,920 | 6,042 | 6,042 | 3.2M | 16.0M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $33.59B | $29.50B | $5.29B | $5.71B | $8.1M | $10.1M | $3.2M | $6.2M |
| Short-term investments | — | — | $13.2M | $13.1M | $13.7M | — | — | — |
| Receivables | $13.01B | $12.91B | $11.0M | $15.2M | $15.6M | $10.9M | — | — |
| Inventory | $2.19B | $1.74B | $3.3M | $2.2M | $2.5M | $1.9M | — | — |
| Total current assets | $53.60B | $51.64B | $25.3M | $41.5M | $50.5M | $23.3M | — | — |
| Property, plant and equipment | $3.58B | $3.57B | $3.7M | $4.3M | $4.7M | $4.4M | — | — |
| Other intangibles | $296.8M | $262.9M | $148.6K | $157.5K | $148.6K | $174.8K | — | — |
| Total assets | $69.30B | $67.95B | $41.7M | $59.5M | $70.1M | $28.8M | — | — |
| Accounts payable | $1.67B | $4.91B | $4.6M | $3.1M | $5.3M | $2.7M | — | — |
| Short-term debt | $2.11B | $5.86B | $5.5M | $411.2K | $4.3M | $2.6M | — | — |
| Total current liabilities | $13.17B | $20.31B | $13.8M | $13.1M | $11.2M | $8.0M | — | — |
| Total liabilities | $13.17B | $22.45B | $13.8M | — | — | — | — | — |
| Retained earnings | -$13.84B | -$10.17B | -$1.4M | $16.3M | $25.1M | $13.7M | — | — |
| Total equity | $56.13B | $45.50B | $27.97B | $35.33B | $47.0M | $20.8M | $12.4M | $9.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.05B | -$9.51B | $1.12B | -$1.3M | -$2.1M | $6.1M | $13.2M | — |
| Depreciation and amortisation | $517.4M | $485.7M | $508.8M | $533.9K | $446.9K | $410.1K | $413.2K | — |
| Capital expenditure | $266.8M | $208.3M | $44.2M | $93.7K | $444.5K | $51.8K | $86.3K | — |
| Investing cash flow | -$341.8M | -$361.3M | -$44.2M | -$3.9M | -$27.1M | -$51.8K | -$86.0K | — |
| Financing cash flow | $9.73B | $33.95B | -$1.39B | $3.3M | $26.6M | $470.1K | -$16.0M | — |
| Dividends paid | — | — | — | — | — | — | $16.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-009000.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $33.2M | $30.7M | $48.0M | $40.1M | $32.31B | $23.02B | $17.86B |
| Gross profit | — | $13.4M | $14.1M | $25.3M | $21.9M | $10.32B | $6.07B | $6.30B |
| Net income | — | $7.6M | $7.6M | $11.3M | -$7.9M | -$6.58B | -$8.73B | -$3.67B |
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |